Rockstar Lunch

Are you looking for an opportunity to network with local senior leaders? If so, this is THE event for you. Join Tim Clackson, President and Chief Executive Officer of Theseus Pharmaceuticals, and Jo Viney, Founder, President, and CEO of Seismic Therapeutic, for an engaging conversation. Registration is for WEST MEMBERS ONLY and will be limited to a maximum of 20 participants to ensure an intimate experience. 


Tim Clackson, Ph.D. is President and Chief Executive Officer of Theseus Pharmaceuticals, a clinical-stage public company focused on developing targeted therapies for cancer patients. Prior to Theseus, Tim served from 2018 to 2021 as President, EVP of R&D, and Chief Technology Officer at Xilio Therapeutics, a then-privately held oncology company developing tumor-selective immunotherapies. From 1994 to 2017, Tim was with ARIAD Pharmaceuticals, in various roles culminating in President of R&D and Chief Scientific Officer. Tim played a key role in the company’s evolution from early research to a global commercial oncology company, and its subsequent acquisition by Takeda. He led the multi-disciplinary R&D team that internally discovered and developed five clinical-stage product candidates, including ICLUSIG® (ponatinib), approved for patients with treatment-resistant Ph+ leukemias; ALUNBRIG® (brigatinib), approved for ALK+ non-small cell lung cancer (NSCLC); and EXKIVITY® (mobocertinib), approved for EGFR Exon20 insertion+ NSCLC. Prior to ARIAD, Tim was a postdoctoral research fellow at Genentech. He received his Ph.D. in Biology from the University of Cambridge, and his B.A. in Biochemistry from the University of Oxford. Tim serves as a director on the boards of Forma Therapeutics, Elevation Oncology and the Massachusetts Biotechnology Council (MassBio).


Jo Viney, Ph.D. is an experienced biotech executive and entrepreneurial scientist who has taken 13 drugs to clinic. Dr. Viney is the Founder, President, and CEO of Seismic Therapeutic, the machine learning immunology company. Prior to founding Seismic, she founded Pandion Therapeutics in 2017 and served as President and CSO until the acquisition by Merck for $1.85B in 2021. Prior to founding Pandion, she worked at Biogen, Amgen, and Immunex. Jo is an independent board director for Finch Therapeutics, Harpoon Therapeutics, Graphite Bio and Lab Central, and is an advisory board member for HotSpot Therapeutics. Jo was featured in Endpoints’ 2019 Special Report on 20 Extraordinary Women, and in FiercePharma’s 2020 Fiercest Women in Life Sciences. Jo is an advocate for workplace inclusiveness. She has served on the board of WEST, a non-profit organization supporting early to mid-career women, including as President 2017-18.


Date and Time:   
March 22, 2022
12:00-1:00 PM EST


Members: $5

Given our mission is to promote women's development in STEM we would like to offer a free spot in our workshops to those in transition between jobs or who cannot afford the ticket price. Please contact [email protected] if you qualify.


Register Here